Navigate Up
Sign In
home |  mail |  workspaces |  moodle |  intranet |  contact 

 Prof. Dr. Cees Cornelisse

Cees Cornelisse was born on June 17, 1941, in Middelburg. After attending the Christelijke HBS voor Walcheren, and fulfilling his military service from 1960-1962, he started his study of Biology at the Free University in Amsterdam from which he graduated in 1969. He did his Ph.D. study in Cytochemistry at the University of Leiden, Dept. of Pathology from 1969-1973, and defended his thesis On the Localization Problem in Enzyme Cytochemistry in January 1974. After a further specialization in Cytochemistry and Cytometry he was appointed as Assistant Professor and later as Associate Professor at the Dept. of Pathology of the University of Leiden. In 1995 he was appointed Full Professor of Molecular Tumor Pathology at the Dept. of Pathology of the Leiden University Medical Center. He retired in June 2006.

His research interests are in the field of cancer genetics and genomics. Initially, his research was focused on the diagnostic and prognostic significance of aneuploidy in solid tumours with emphasis on breast cancer. His group was the first to report aneuploidy in colorectal adenomas. These studies were later extended by molecular genetic approaches focused on the identification of tumour suppressor gene loci. His group did pioneering work on the construction of a breast cancer allotype which culminated in the identification of E-cadherin as tumorsuppressor gene in lobular breast cancer in a collaboration with a group from the unvesrity of Ghent, Belgium. In addition to the study of somatic changes in breast cancer, his group embarked on a long-standing research program on familial breast cancer in close collaboration with members of the Breast Cancer Linkage Consortium. Milestones of this program were the contributions to the localization and identification of the BRCA2 cancer susceptibility gene, risk profiles associated with BRCA1,2 germline mutations and the identifications of large genomic deletions in Dutch BRCA1 carriers. A second research program concentrates on the identification of the tumor suppressor gene involved in hereditary head and neck paragangliomas. The discovery of germline mutations in a SDHD, a subunit of the mitochondrial complex II in collaboration with a group from Pittsburgh, USA, was milestone of this second program. More recently he developed a model to explain the parent –of-origin effect on the transmission of the tumours in pedigrees, implying a second, imprinted tumour suppressor gene.

Prof. Cornelisse has supervised or co-supervised more than 20 Ph.D. students and is author/co-author of more than 270 articles in peer-reviewed international scientific journals. He was rated among the 10 most cited Dutch scientists in a 2002 bibliometric analysis carried out by Elsevier.

Prof. Cornelisse is a Knight in the Order of the Dutch Lion.

Selected Publications

  • Van de Vijver M, Van de Bersselaar R, Devilee P, Cornelisse CJ, Peterse J, Nusse R: Amplification of the neu (c-erb B-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erb A oncogene. Mol Cell Biol 7, 2019-20232, 1987.
  • Van de Mey AGL, Maaswinkel-Mooy PD, Cornelisse CJ, Van de Kamp JJP: Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. The Lancet ii, 1291-1294, 1990.
  • Devilee P, Van Vliet M, Van Sloun P, Kuipers-Dijkshoorn N, Hermans, J, Pearson PL, Cornelisse CJ: Allelotype of human breast cancer: a second site of loss of heterozygosity is on chromosome 6q, Oncogene 6, 1705-1711, 1991.
  • Devilee P, Cornelis R, Bootsma A, Bardoel A, Van Vliet M, Van Leeuwen I, De Klein A, Lindhout D, Vasen H, Cornelisse CJ, Meera Khan P: Linkage to markers for the chromosome region 17q12-q21 in 13 Dutch breast cancer kindreds, Am J Hum Genet 52, 730-735, 1993.
  • Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE and the Breast Cancer Linkage Consortium: Risks of cancer in BRCA1-mutation carriers. The Lancet, March 19, 692-695, 1994.
  • Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyeb K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, DaLy PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer suscepitbility gene, BRCA2, to chromosome 13q12-13, Science 265, 2088-2090, 1994.
  • Wooster R, Cleton-Jansen AM, Collins N, Mangion J, Cornelis RS, Cooper CS, Gusterson BA, Ponder BAJ, Von Deimling A, Wiestler OD, Cornelisse CJ, Devilee P, Stratton MR, Instability of short tandem repeats (microsatellites) in human cancers. Nature Genet 6, 152-156, 1994.
  • Hogervorst FBL, Cornelis RS, Bout M, Van Vliet M, Oosterwijk JC, Olmer R, Bakker E, Klijn JGM, Vasen HFA, Meijers-Heijboer EJ, Menko FH, Cornelisse CJ, Den Dunnen JT, Devilee P, Van Ommen GJB: Rapid detection of BRCA1 mutations by the protein truncation test. Nature Genetics 10, 208-212, 1995.
  • Wooster R, Bignell FG, Lancaster J, Swift S, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hasmim Y, Smith A, Connor F, Arason A, Gudmunsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson, Barkadottir RB, Easton DF, B entley DR, Futreal PA, Ashworth A, Stratton MR: Identification of the breast cancer susceptibility gene BRCA2, Nature 378, 789-792, 1995.
  • Berx G, Cleton-Jansen AM, Nollet F, De Leeuw WJF, Van de Vijver MJ, Cornelisse C, Van Roy F: E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers, EMBO J, 14, 6107-6115, 1995.
  • The Fanconi anaemia/Breast cancer Consortium: Positional cloning of the Fanconi anaemia group A gene, Nature Genet 14, 324-328, 1996.(Group 5: Annemarie Cleton-Jansen, Elna W. Moerland and Cees J. Cornelisse).
  • Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AMW, Hogervorst F, Brohet R, Ligtenberg MJL, Teugels E, van der Luijt R, van der Hout AH, Gille JJP, Pals G, Jedama I, Olmer R, van Leeuwen I, Newman B, Plandsoen M, van der Est M, Brink G, Hageman S, Arts PJW, Bakker MM, Willems HW, cvan der Looij E, Neyns B, Bonduelle M, Jansen R, oosterwijk JC, Sijmons R, Smeets HJM, van Asperen CJ, Meijers-Heijboer H, Klijn JGM, de Greve J, King M-C, Menko FH, Brunner HG, Halley D, van Ommen GJ, Vasen HFA, Cornelisse CJ, van 't Veer LJ, de Knijff P, Bakker E, Devilee P: A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian Hereditary Breast and Ovarian cancer families. Am J Hum Genet 60: 1041-1049, 1997.
  • Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Dr_sedau, Hogervorst FBL, Hageman S, Arts PJW, Ligtenberg MJLL, Meijers-Heijboer H, Klijn JGM, Vasen HFA, Cornelisse CJ, van ‘t Veer LJ, Bakker E, van Ommen GJG, Devilee P: BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet 17: 341-345, 1997.
  • Liefers GJ, Cleton-Jansen AM, van de Velde CJH, Hermans JH, van Krieken JHJM, Cornelisse CJ, Tollenaar RAEM: Micrometastases and survival in stage II colorectal cancer. NEJM 339: 223-228, 1998.
  • Van Schothorst EM, Jansen JC, Grooters E, Prins DE, Wiersinga JJ, van der Mey AG, van Ommen GJ, Devilee P, Cornelisse CJ. Founder effect at PGL1 in hereditary head and neck paraganglioma families from The Netherlands. Am J Hum Genet 63, 468-473, 1998.
  • Boveé JVM, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiau AHM, Bakker E, van Hul W, Cornelisse CJ, Hogendoorn PCW: EXT-mutation analysis and loss of heterozygosity in sporadic hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 1999;65:689-698.
  • Wijnen J, de Leeuw W, Vasen H, van der Klift H, Møller P, Sormorken A, Meijers-Heijboer H, Lindhout D, Menko F, Vossen S, Möslein G, Tops C, Bröcker-Vriends A, Wu Y, Hofstra R, Sijmons R, Cornelisse C, Morreau H, Fodde R: Familial endometrial cancer in femal carriers of MSH6 germline mutations. Nat Genet 23: 142-144, 1999.
  • Baysal BE, Ferrell RE, Willet-Brozick JE, Lwarence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PEM, Rubinstein WS, Myeres EN, Richard III CW, Cornelisse CJ, Devilee P, Devlin B. Mutations in SDHD, a mirochondrial complex II gene in hereditary paraganglioma, Science 2000, 287: 848-851.
  • Sieben, N.L.G, Kolkman-Uljee, S.M., Flanagan, A.M., Cessie, S. le, Cleton-Jansen, A.M., Cornelisse, C.J. & Fleuren, G.J. Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. American Journal of Pathology,2003,162, 1095-1101.
  • Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Research 2003;63: 8153-7.
  • Hensen EF, Jordanova ES, Van Minderhout JHM, Hogendoorn PCW, Taschner PW, ven der Mey AGL, Devilee P, Cornelisse CJ: Somatic loss of maternal chromosome 11 causes parent-of origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene, 2004, 20:4076-4083.
  • Corver WE, Ter Haar NT, Dreef EJ, Miranda NF, Prins FA, Jordanova ES, Cornelisse CJ, Fleuren GJ: High resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal; cell subpopulations in paraffin-embedded tissues. J Pathol 2005, 206, 233-241.
  • Van Beers EH, van Welsem T, Wessels LF, Li Y, Oldenburg EA, Devilee P, Cornelisse CJ, Veerhoef S, Hogervorst FB, van ‘t Veer LJ, Nederlof PM:Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight different sets of genomic aberrations. Cancer Res 2005, 65, 822-827.
  • Lakhani SR, Reis-Filho JS, Fulford L, Penault-Lorca F, van de Vijver N, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamamnn U, Cornelisse CJ, Devilee P,  Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley, Lalloo F, Evans G, Maaugard C, Meijers-Heijboer, Klijn JG, Olah E, Gustyerson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF, Breast Canacer Linkage Consortium: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotypes. Clin Cancer Res 2005, 11, 5175-5180.
  • Sieben NL, Oosting J, Flanagan AM, Prat J, Roemen GM, Kolkman-Uljee SM, van Eijk R, Cornelisse CJ, Fleuren GHJ, van Engeland M: Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 2005 23, 7257-7264.
  • Kumar R, Neilsen PM, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansaen AM, Caallen DF, FBXO31 is the chromosome 16q24.3 senescence gene, a candidate tumor suppressor and a component of an SCF complex. Cancer Res 2005, 65, 11304-11313
  • Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ. Hoogerbrugge N, van Leeuwen I, Vasen HF, Cleton-Jansen AM, Kraan J, Houwing-Duistermaat JJ, Morreau H, Cornelisse CJ, Devilee P,  Clin Cancer Res 2006, 121, 1693-1670
  • Douwes Dekker PB, Kuipers-Dijkshoorn NJ, Baelde HJ, van der Mey AG, Hogendoorn PC, Cornelisse CJ: Basic fibroblast growth factor and fibroblastic growth factor receptor-1 may contribute to head and neck paraganglioma development by an autocrine or paracrine mechanism, Hum Pathol 2007, 38, 79-85.
  • De Bock GH, Mourits MJ, Schutte M, Krol-Warmerdam EM, Seynave C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JGH: Association between CHEK2*1100delC germline mutation and estrogen receptor status, Int J Gynecol Cancer 2006,16 Suppl 2, 552-555,
  • Schmidt MK, Tollenaar RA, de Kemp SR, Broeke A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, van ‘ t Veer LJ: Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation, J Clin Oncol 2007, 25, 64-69.
  • Corver WE, Middeldorp A, ter Haar NT, Jordanova ES, van Puijenbroek M, van Eijk R, Cornelisse CJ, Fleuren GJ, Morreau H, Oosting J, van Wezel T, Genome-wide allelic state analysis on gflow-sorted tumor fractions provides an accurate measure of chromosomal aberrations, Cancer Res 2008, 66, 10333-10340
  • Hensen EF, Jansen JC, Siemers MD, Oosterwijk JC, Vriends AH, Corssmit EP, Bayley JP, van der Mey AG, Cornelisse CJ, Devilee P, The Dutch founder mutation SDHD D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family, Eur J Hum Genet 2010, 18, 62-66.
  • Bayley JP, van Minderhout I, Hogendoorn PC, Cornelisse CJ, van der Wal A, Prins FA, Teppema L, Dahan A, Devilee, Taschner PE, Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma, PLoS One 2009, 4, e7987
  • Hensen EF, Siemers MD, Jansen JC, Corssmit EP, Romijn JA, Tops CM, van der Mey AG, Devilee P, Cornelisse CJ, Bayley JP, Vriends AH, Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients, Clin Endocrinol 2011, 75, 650-655
  • Hensen EF, van Duinen N, Jansen JC, Corssmit EP, Tops CM, Romijn JA, Vriends AH, van der Mey AG, Cornelisse CJ, Devilee P, Bayley JP, High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands, Clin Genet 2012, 81, 284-288


Cees Cornelisse.jpg 


Molecular Tumor Pathology -  Life Sciences

P.O. Box 94
NL-4330 AB Middelburg
Office hours: by appointment
Tel. 0118-655500 / fax 0118-655508